Courageous. Focused. Passionate.

Pioneering Development of Life-Changing Treatments by Leveraging the Untapped Mechanisms of the Lysosome

Diseases for which medicine offers few effective options-advanced cancer, neurodegenerative diseases, lysosomal storage diseases and autoimmune diseases-persist because they involve very complex and interrelated cellular operations. Bexion is committed to unlocking the workings of the lysosome, the key cellular orchestrator, to provide patients effective, non-toxic therapies where none currently exist.

Watch the video


Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson

In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.

– Our Platform

An innovative, targeted approach to treating cancer

For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.

By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials


Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More


Bexion Resources


Learn More
View All Resources


    Press Release

    Bexion Pharmaceuticals Receives Study May Proceed Letter from FDA for a Phase 1b/2 Clinical Trial of BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

    September 29, 2021

    FOR IMMEDIATE RELEASE Covington, KY,  29 September 2021               Bexion Pharmaceuticals, Inc. announced today that a Study May Proceed letter has been received from the US Food and Drug Administration (FDA) for the Investigational New Drug Application (IND) for BXQ-350 to initiate a Phase 1b/2 clinical trial in newly diagnosed stage 4 metastatic colorectal cancer patients. ... Read More

      Press Release

      Bexion Pharmaceuticals, Inc. to Present at the 2021 Discovery on Target Conference

      September 17, 2021

      FOR IMMEDIATE RELEASE [Covington, KY---September 17, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that Gilles Tapolsky PhD, MBA, Bexion’s Vice President, Pharmacology will be virtually presenting preclinical and clinical data of the Company’s lead compound, BXQ-350.  The presentation will be made at the Discovery on Target (DOT) Conference in the Immunology and ... Read More

      View All Media